ivermectin - versus placebo - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.52 [0.10, 2.64]< 127%2 studies (2/-)78.6 %some concernnot evaluable moderatecrucial-
clinical improvement (7-day) 0.90 [0.77, 1.06]> 10%1 study (1/-)9.7 %NAnot evaluable important-
death or ventilation 0.89 [0.30, 2.64]< 10%1 study (1/-)58.4 %NAnot evaluable important-
hospital discharge 1.14 [0.71, 1.84]> 10%2 studies (2/-)70.9 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.20 [0.00, 8.69]< 10%1 study (1/-)79.4 %NAnot evaluable important-
viral clearance 0.92 [0.77, 1.09]> 10%1 study (1/-)17.3 %NAnot evaluable important-
viral clearance by day 7 0.91 [0.77, 1.08]> 10%2 studies (2/-)13.7 %lownot evaluable highimportant-
ICU admission 0.90 [0.30, 2.70]< 10%1 study (1/-)57.4 %NAnot evaluable non important-

safety endpoints 00

adverse events 1.00 [0.20, 5.07]< 10%1 study (1/-)50.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.